The impact of vitamin D status on cardiometabolic effects of fenofibrate in women with atherogenic dyslipidemia.

Abstract

Vitamin D deficiency is a risk factor for cardiometabolic disease. The aim of this study was to determine the role of vitamin D status in the impact of fenofibrate on plasma levels of cardiometabolic risk factors. The study population (n=61) consisted of three matched groups of women with atherogenic dyslipidaemia: vitamin D-naïve women withvitamin Dinsufficiency (group A), women receiving vitamin D preparations because ofvitamin Ddeficiency (group B), as well as vitamin D-naïve women with normalvitamin Dstatus (group C), who were treated with micronized fenofibrate (200mg daily). Glucose homeostasis markers, plasma lipids, as well as plasma levels of 25-hydroxyvitamin D, uric acid, high-sensitivity C-reactive protein (hsCRP), fibrinogen and homocysteine were determined at the beginning of the study and 6months later. At entry, group A was characterized by lower levels of 25-hydroxyvitamin D, reduced insulin sensitivity and higher concentrations of uric acid, hsCRP, fibrinogen and homocysteine. Apart from a weaker effect on HDL-cholesterol and triglycerides in group A, there were no differences between the treatment arms in the effect of fenofibrate on plasma lipids. However, only in groups B and C the drug improved insulin sensitivity and reduced circulating levels of uric acid and hsCRP, as well as increased levels of 25-hydroxyvitamin D and these effects correlated with the degree of improvement in insulin sensitivity. Treatment-induced increase in homocysteine was observed only in group A. The results of the study indicate that cardiometabolic effects offibrates may depend on thevitamin Dstatus of patients.